Metformin can block precancerous progression to invasive tumors of bladder through inhibiting STAT3-mediated signaling pathways

Abstract

BackgroundMetformin is the first line of oral antidiabetic drug in the biguanide class for treatment of type 2 diabetes. Increasing evidence has suggested that it is a potential anti-tumor drug. However, the mechanisms underlying inhibiting tumor development remain elusive, especially in bladder tumors.MethodsT24 and J82 cell lines were used as an in vitro model, and 24 female SD rats were used to build an N-methyl-N-nitrosourea (MNU)-induced orthotopic rat bladder cancer model. Transfection of lentivirus-based shRNA was used to construct the STAT3-KNOCKDOWN T24 cell line. After metformin treatment, the viability of bladde cancer cells was determined by CCK8. Cell cycle distribution and apoptosis were assessed by flow cytometry. The migration and invasion abilities of cells were evaluated by wound healing and transwell asssays. The inactivation of stat3 pahtway was examined by qRTPCR, western blot and Immunofluorescence.ResultsMetformin can effectively inhibit precancerous progression to invasive cancer in an MNU-induced rat orthotopic bladder tumor model, although it could not completely suppress normal cells transforming into tumor cells. While the MNU could induce 50 % rats (4/8) to develop invasive bladder cancers, the rats co-administrated with metformin failed to develop invasive tumors but retained at precancerous or non-invasive stages, exhibiting as dysplasia, papillary tumor and/or carcinoma in situ (CIS). Accordingly, phosphorylation of signal transducer and activator of transcription 3 (STAT3), which is a well known oncogene, was significantly inhibited in the tumors of rats treated with metformin. In vitro experiments revealed that the metformin could efficiently inhibit STAT3 activation, which was associated with the cell cycle arrest, reduction of cell proliferation, migration and invasiveness, and increase in apoptotic cell death of bladder cancer cell lines.ConclusionsThese findings provide for the first time the evidence that metformin can block precancerous lesions progressing to invasive tumors through inhibiting the activation of STAT3 pathway, and may be used for treatment of the non-invasive bladder cancers to prevent them from progression to invasive tumors.Electronic supplementary materialThe online version of this article (doi:10.1186/s13046-015-0183-0) contains supplementary material, which is available to authorized users.

Effects on Energy Metabolism of Two Guanidine Molecules, (Boc)2 -Creatine and Metformin

“…It was already known that metformin impairs the proliferation of several tumor cells Salani et al, 2013;W€ urth et al, 2013;Barbieri et al, 2015;Cheng and Lanza-Jacoby, 2015;Pan et al, 2015] and this ability was confirmed by the data obtained by our group (Fig. 8).…”

New insight for metformin against bladder cancer

“…Several risk factors, such as smoking, paint and human papillomavirus infection, have been involved in carcinogenesis of urinary bladder [4]. A recent meta-analysis of 15 cohort studies concluded that pre obese has a significantly increased risk of bladder cancer by 7%, while obesity increases the risk of bladder cancer by approximately 10%.…”

Mucoadhesive Cationic Polypeptide Nanogel with Enhanced Penetration for Efficient Intravesical Chemotherapy of Bladder Cancer

“…All animals received care in compliance with the guidelines outlined in the Guide for the Care and Use of Laboratory Animals, and all procedures were approved by the Animal Care and Use Committee of Jilin University. As depicted in Scheme 1 , the orthotopic BC was induced by intravesical instillation of MNU every other week for a total of eight weeks 26. To confirm whether the BC was successfully induced or not, at the end of the intravesical instillation of MNU, the histopathological examination was performed.…”